Last updated: April 24, 2026
Which suppliers produce glimepiride drug substance (API)?
A “glimepiride supplier” in practice splits into two procurement routes: API manufacture (chemical drug substance) and finished-dose supply (tablets packed for patients). The table below lists global, commercially active sources that distribute or manufacture glimepiride for downstream pharma use, including generic makers and contract manufacturing channels.
Glimepiride API and API-channel suppliers (global)
| Supplier |
Procurement role |
Typical offering |
Coverage strength |
Notes |
| Aurobindo Pharma |
API and formulation |
Glimepiride API + generics |
Broad |
Major generic supplier with US/EU-market presence. |
| Cipla |
Formulation + supply chain |
Glimepiride tablets (and supply network) |
Strong |
Markets glimepiride via multiple jurisdictions. |
| Sun Pharma |
Formulation + supply chain |
Glimepiride products |
Strong |
Large generic portfolio; commonly supplies established strengths. |
| Sandoz (Novartis) |
Formulation |
Glimepiride products in regulated markets |
Strong |
Brand/generic presence by country. |
| Dr. Reddy’s |
API and formulation |
Glimepiride API + generics |
Strong |
Integrated supply chain across multiple markets. |
| Teva |
Formulation + supply chain |
Glimepiride tablets |
Strong |
Large-scale generic distribution. |
| Mylan (Viatris) |
Formulation |
Glimepiride products |
Strong |
Generic supply capability across regulated geographies. |
| Lupin |
Formulation + supply chain |
Glimepiride products |
Strong |
Active generic manufacturer. |
| Torrent Pharmaceuticals |
Formulation |
Glimepiride products |
Strong |
Broad India and export footprint. |
| CordenPharma / CMOs (API-formulated partnerships) |
Contract manufacturing channel |
Often works as a manufacturing partner depending on project |
Variable |
CMO involvement is project-specific; glimepiride is commonly contracted via finished-dose routes rather than sole API OEM disclosure. |
Business use note (procurement): Many buyers qualify suppliers through DMF/CEP filings, regulatory inspection history, and traceable commercial COA stability. In practice, GLIMEPIRIDE is widely sourced, and the fastest route is usually buying through the buyer’s existing generic supply framework (Viatris, Teva, Dr. Reddy’s, Sandoz, etc.) or contracting with an India/EU API/formulation stack that already holds dossier-ready documentation in target regions.
Which suppliers sell glimepiride finished-dose tablets?
Finished-dose tablet supply is the default procurement route for hospitals, distributors, and brand replacement programs. The list below captures active global generic manufacturers and large distributors.
Glimepiride finished-dose manufacturers (tablets)
| Manufacturer |
Typical supply form |
Market presence |
Common procurement role |
| Aurobindo Pharma |
Tablets (strengths depend on jurisdiction) |
US/EU and emerging markets |
Distributor-facing generic supply |
| Cipla |
Tablets |
Broad |
Tender and hospital channels |
| Sun Pharma |
Tablets |
Broad |
Portfolio supplier |
| Sandoz |
Tablets |
EU/US and other regulated markets |
Regulated-market supply |
| Dr. Reddy’s |
Tablets |
Regulated and emerging |
Tender-ready |
| Teva |
Tablets |
Regulated |
Long-term panel supplier |
| Viatris (Mylan) |
Tablets |
Regulated |
High-volume generic supply |
| Lupin |
Tablets |
Broad |
Contract and tender supply |
| Torrent |
Tablets |
India and export |
Regional procurement |
| Local brand owners (varies by country) |
Tablets |
Country-specific |
Labeler/distributor role |
How do suppliers differ for API vs finished-dose buying?
Procurement decisions usually hinge on whether the buyer needs commercial API or finished tablets.
API procurement
Common supplier criteria:
- Drug Master File (DMF) access for the target region (commonly US) and/or CEP coverage for EU-style dossier pathways.
- CoA release specs aligned to market pharmacopoeia requirements (USP/EP/JP) and stability data.
- Batch traceability and change-control documentation for polymorph, particle size, and impurity profiles.
Finished-dose procurement
Common supplier criteria:
- GMP status for tablet manufacturing site(s).
- Stability at marketed storage conditions and shelf-life commitments.
- Bioequivalence pathway evidence where required (especially for regulated markets).
- Packaging and labeling compliance for local tender requirements.
What regulatory documents signal supplier readiness for glimepiride?
In diabetes medicine supply chains, qualified suppliers typically provide:
- Certificate of Analysis (CoA) per batch
- Spec sheets for identity, assay, impurities, residual solvents (where applicable)
- GMP inspection history for relevant manufacturing sites
- DMF/CEP status for API route procurement
For global listings and dossier-linked supplier visibility, regulators and databases commonly used by procurement teams include:
- US FDA Drugs@FDA for product-level approvals (finished-dose)
- EMA-related pathways for EU product authorizations
- National health authority product registries
- DMF/CEP databases (API-level)
Supplier strategy: picking the right category
For glimepiride, buyers usually pick between three routes:
- Tier-1 generic finished-dose supplier
- Fast qualification, low regulatory friction in established markets.
- API OEM / API-capable generic manufacturer
- Best for in-house formulation or contract formulation via a second partner.
- API through established generic panel suppliers
- Practical compromise when dossier access matters but the buyer does not want to run API qualification alone.
Key Takeaways
- Glimepiride sourcing is broad across major global generic manufacturers with established finished-dose and/or API supply chains.
- For procurement speed and lower regulatory overhead, finished-dose suppliers (Teva, Viatris, Sun Pharma, Cipla, Dr. Reddy’s, Sandoz, Aurobindo, Lupin, Torrent) are typically the most direct route.
- For in-house development or contract manufacturing, prioritize API-capable suppliers with DMF/CEP readiness, batch traceability, and impurity/spec controls.
- Supplier selection should map to the buyer’s route (API vs tablet) and the target jurisdiction’s dossier and GMP expectations.
FAQs
1) Can glimepiride be sourced from multiple countries reliably?
Yes. Glimepiride is a mature generic active with widespread global manufacturing and finished-dose availability through large generics suppliers.
2) Are API and finished-dose suppliers always the same companies?
No. Many firms lead in finished-dose distribution while only certain sites produce API or hold the most accessible dossier artifacts for API procurement.
3) What matters most for qualifying a glimepiride API supplier?
Dossier readiness (DMF/CEP), impurity profile control, GMP inspection record for the API site, and batch traceability with consistent CoA specs.
4) What matters most for qualifying a glimepiride tablet supplier?
Tablet-site GMP status, stability data, bioequivalence pathway for the target market where required, and packaging/label compliance.
5) Which supplier type reduces time-to-procure for tenders?
Finished-dose suppliers with proven tender history and established market registrations tend to compress qualification timelines.
References (APA)
[1] FDA. (n.d.). Drugs@FDA: Glimepiride products and approvals. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] EMA. (n.d.). European Medicines Agency: Search medicines (glimepiride). European Medicines Agency. https://www.ema.europa.eu/en/medicines
[3] WHO. (n.d.). WHO Model List of Essential Medicines (diabetes medicines including glimepiride). World Health Organization. https://list.essentialmeds.org/
